This brand name is authorized in Germany
The drug SIMVAZET contains a combination of these active pharmaceutical ingredients (APIs):
|
1
Ezetimibe
UNII EOR26LQQ24 - EZETIMIBE
|
|
Ezetimibe is in a new class of lipid-lowering compounds that selectively inhibit the intestinal absorption of cholesterol. The molecular target of ezetimibe is the sterol transporter, Niemann-Pick C1-Like 1 (NPC1L1), which is responsible for the intestinal uptake of cholesterol. |
|
2
Simvastatin
UNII AGG2FN16EV - SIMVASTATIN
|
|
Simvastatin has a potent activity in inhibiting HMG-CoA reductase (3-hydroxy–3-ethylglutaryl-CoA-reductase). Simvastatin has been shown to reduce both normal and elevated LDL-C concentrations. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| C10BA02 | Simvastatin and ezetimibe | C Cardiovascular system → C10 Lipid modifying agents → C10B Lipid modifying agents, combinations → C10BA Combinations of various lipid modifying agents |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: DE | Bundesinstitut fĂźr Arzneimittel und Medizinprodukte | Identifier(s): 13970510, 13970533, 13970556, 13970562, 13970579, 13970585, 13970591, 13970616 |
Š All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
